What do systematic reviews say?

CBT with therapist support vs fatigue information leaflet only

The review found no eligible studies for this question.

• Interventions for fatigue in inflammatory bowel disease 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Physical activity advice plus omega 3 vs no physical activity advice plus omega 3

The review found no eligible studies for this question.

• Interventions for fatigue in inflammatory bowel disease 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Electroacupuncture vs no treatment

• Interventions for fatigue in inflammatory bowel disease 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 34 participants
  Low

Electroacupuncture vs sham electroacupuncture

• Interventions for fatigue in inflammatory bowel disease 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 36 participants
  Low

H2 receptor antagonists vs placebo or no prophylaxis

The review found no eligible studies for this question.

• Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Proton pump inhibitors (PPI) vs placebo or no prophylaxis

The review found no eligible studies for this question.

• Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Antacids vs placebo or no prophylaxis

The review found no eligible studies for this question.

• Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Sucralfate vs placebo or no prophylaxis

The review found no eligible studies for this question.

• Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

H2 receptor antagonists vs proton pump inhibitors

The review found no eligible studies for this question.

• Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

H2 receptor antagonists vs antacids

The review found no eligible studies for this question.

• Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

H2 receptor antagonists vs sucralfate

The review found no eligible studies for this question.

• Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Antacids vs sucralfate

The review found no eligible studies for this question.

• Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Flumazenil vs placebo

• Flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy 2017 · Cochrane Headline outcomes only
  no estimate extracted
  11 studies · 842 participants
  Low

Budesonide vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)

Budesonide showed no clear difference in serious adverse events compared with mesalazine (low certainty).

• Interventions for treating collagenous colitis 2017 · Cochrane Headline outcomes only
  RR 0.12 [0.01, 2.21]
  1 study · 55 participants
  Low

Mesalamine vs placebo

Mesalamine showed no clear difference in serious adverse events compared with placebo (low certainty).

• Interventions for treating collagenous colitis 2017 · Cochrane Headline outcomes only
  RR 4.44 [0.49, 40.29]
  1 study · 62 participants
  Low

Budesonide vs placebo

It is very uncertain whether budesonide changes serious adverse events compared with placebo (very low certainty).

• Interventions for treating collagenous colitis 2017 · Cochrane Headline outcomes only
  RR 1.11 [0.15, 8.01]
  4 studies · 175 participants
  Very low

Ursodeoxycholic acid vs placebo

The review found no eligible studies for this question.

• Pharmacological interventions for primary sclerosing cholangitis 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Erythrocytapheresis vs phlebotomy

• Interventions for hereditary haemochromatosis 2017 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 38 participants
  Very low

Lactulose vs lactitol

It is very uncertain whether lactulose changes serious adverse events compared with lactitol (very low certainty).

• Non‐absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and… 2016 · Cochrane Headline outcomes only
  RR 1.56 [0.84, 2.88]
  9 studies · 245 participants
  Very low

High‐dose corticosteroids vs moderate‐dose or no corticosteroids

High‐dose corticosteroids probably leads to higher serious adverse events compared with moderate‐dose or no corticosteroids (moderate certainty).

• Interventions for the treatment of metastatic extradural spinal cord compression in adults 2015 · Cochrane Headline outcomes only
  RR 8.02 [1.03, 62.37]
  2 studies · 77 participants
  Moderate